Substituted 4-Phenyl Pyridines
US-2017050993-A1 · Feb 23, 2017 · US
Fosnetupitant chloride hydrochloride having improved stability
US11312698B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-11312698-B2 |
| Application number | US-202016896135-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jun 8, 2020 |
| Priority date | Nov 29, 2011 |
| Publication date | Apr 26, 2022 |
| Grant date | Apr 26, 2022 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Fosnetupitant chloride hydrochloride having improved stability, characterized by the following chemical structure:
First claim
Opening claim text (preview).
What is claimed is: 1. Fosnetupitant chloride hydrochloride having the following formula: wherein the fosnetupitant chloride hydrochloride comprises less than 0.7% degradants via mass degradation under air and ambient conditions for a period of 80 days. 2. The fosnetupitant chloride hydrochloride of claim 1 , wherein the degradants comprise netupitant. 3. A pharmaceutical composition comprising one or more pharmaceutically acceptable excipients and fosnetupitant chloride hydrochloride having the following formula: wherein the fosnetupitant chloride hydrochloride comprises less than 0.7% degradants via mass degradation under air and ambient conditions for a period of 80 days. 4. The pharmaceutical composition of claim 3 , wherein the degradants in the fosnetupitant chloride hydrochloride comprise netupitant. 5. An injectable pharmaceutical composition comprising one or more pharmaceutically acceptable excipients and fosnetupitant chloride hydrochloride having the following formula: wherein the fosnetupitant chloride hydrochloride comprises less than 0.7% degradants via mass degradation under air and ambient conditions for a period of 80 days. 6. The injectable pharmaceutical composition of claim 5 , wherein the degradants in the fosnetupitant chloride hydrochloride comprise netupitant. 7. Fosnetupitant chloride hydrochloride having the following formula: wherein the fosnetupitant chloride hydrochloride is in the form of an anhydrate; and wherein the fosnetupitant chloride hydrochloride comprises less than 0.7% degradants via mass degradation under air and ambient conditions for a period of 80 days. 8. The fosnetupitant chloride hydrochloride of claim 7 , wherein the degradants comprise netupitant. 9. A pharmaceutical composition comprising one or more pharmaceutically acceptable excipients and fosnetupitant chloride hydrochloride having the following formula: wherein the fosnetupitant chloride hydrochloride is in the form of an anhydrate; and wherein the fosnetupitant chloride hydrochloride comprises less than 0.7% degradants via mass degradation under air and ambient conditions for a period of 80 days. 10. The pharmaceutical composition of claim 9 , wherein the degradants in the fosnetupitant chloride hydrochloride comprise netupitant. 11. An injectable pharmaceutical composition comprising one or more pharmaceutically acceptable excipients and fosnetupitant chloride hydrochloride having the following formula: wherein the fosnetupitant chloride hydrochloride is in the form of an anhydrate; and wherein the fosnetupitant chloride hydrochloride comprises less than 0.7% degradants via mass degradation under air and ambient conditions for a period of 80 days. 12. The injectable pharmaceutical composition of claim 11 , wherein the degradants in the fosnetupitant chloride hydrochloride comprise netupitant.
Assignees
Inventors
Classifications
Purification; Separation; Stabilisation; Desodorisation of organo-phosphorus compounds (of natural phosphatides C07F9/103; phosphines C07F9/5095) · CPC title
to which a second hetero atom is attached (nitro radicals C07D213/61) · CPC title
the ring forming part of a bridged ring system, e.g. quinuclidine (8-azabicyclo [3.2.1] octanes A61K31/46) · CPC title
not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin · CPC title
Anxiolytics · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US11312698B2 cover?
- Fosnetupitant chloride hydrochloride having improved stability, characterized by the following chemical structure:
- Who is the assignee on this patent?
- Helsinn Healthcare Sa
- What technology area does this patent fall under?
- Primary CPC classification C07D401/04. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Apr 26 2022 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 2 related publications on this page (citations in our corpus or others sharing the same primary CPC).